Question 1

Am I eligible for this trial based on my previous treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies clinical trial (NCT05006716). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of BGB-16673?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies clinical trial (NCT05006716). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies clinical trial (NCT05006716). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies clinical trial (NCT05006716). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies clinical trial (NCT05006716). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies clinical trial (NCT05006716). Contact the study team or your healthcare provider for specific answers.

What this study is about